Bank of Nova Scotia has taken a significant step by filing a preliminary pricing supplement for its Enhanced Trigger Jump Securities. This filing, dated November 12, 2026, signifies the bank's intention to offer a new financial product linked to the performance of Palantir Technologies Inc. The securities will not pay interest and carry risks that could lead to significant losses for investors.
This move is noteworthy as it reflects the bank's strategy to diversify its investment offerings amidst a competitive landscape in the state commercial banking sector. By introducing these securities, Bank of Nova Scotia aims to attract investors who are willing to engage with higher-risk, equity-based returns.
Background
Bank of Nova Scotia, also known by its ticker symbol BNS, operates in the state commercial banking sector, as classified under SIC 6022. The bank is listed on the New York Stock Exchange and has a long history of providing various financial services. Recent filings include multiple 424B2 submissions on November 13, 2026, indicating ongoing activity in its capital markets.
What the Filing Says
The filing states, "The information in this preliminary pricing supplement is not complete and may be changed." It also outlines the structure of the Enhanced Trigger Jump Securities, which are due on or about June 5, 2028, and are linked to the common stock of Palantir Technologies Inc. Investors will receive a fixed upside payment if the final share price meets or exceeds a specified trigger level.
Impact
This new offering may appeal to investors looking for equity-linked returns, but it comes with inherent risks, including the potential loss of principal. The securities are designed for those who can tolerate risk in exchange for the possibility of higher returns. The introduction of these securities could influence other banks in the state commercial banking sector to consider similar products to remain competitive.
What's Next
The filing does not say what happens next, but the bank is expected to finalize the pricing and details of these securities in the coming weeks.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










